What this site is — and what it is not.

What Shop Tirzepatide is

Shop Tirzepatide catalogs the peer-reviewed research on tirzepatide — the dual GIP and GLP-1 receptor agonist that is FDA-approved for type 2 diabetes (2022), chronic weight management (2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (2024) — arranged like a product-design reference.

The site is organized like a product-design reference. Each major trial in the SURPASS and SURMOUNT phase 3 programs is treated as a named component with its own summary, citation, and place in the index. The goal is to make a large clinical literature legible — to put the trial numbers in plain English, with the source attached, so a reader can see exactly where each claim comes from.

What this site is not

There is no clinic here and no clinician on staff; the site diagnoses nothing, treats nothing, and gives no medical advice. It makes, stocks, and sells nothing, and it operates no pharmacy, telehealth service, or compounding facility. It is not affiliated with any manufacturer, distributor, prescriber, or vendor.

The word "shop" in the domain is editorial framing — a position the publisher occupies relative to the literature (a curated catalog of trials and approved indications) — not a claim about the site's services. We do not stock, fulfill, prescribe, or ship tirzepatide. Decisions about whether tirzepatide is appropriate for a given person, and at what dose, belong to a licensed clinician who knows the patient's history.

Editorial standards

Every quantitative claim on the site — dose value, percentage, hazard ratio, half-life — cites a specific primary source listed on the references page. Where a randomized controlled trial exists, the trial is the source. Where the FDA label is the authoritative reference for dosing or storage, the label is cited. Where pharmacokinetic claims are made, the source is the published population PK model.

We use the international nonproprietary name (INN) — tirzepatide — exclusively. We do not use brand names, manufacturer names, or competitor brand names anywhere on the site. We do not anonymize or paraphrase the trial registry identifiers; ClinicalTrials.gov numbers are cited as published.

Where the literature is uncertain — for example, the human relevance of the rodent thyroid C-cell signal, or the long-term significance of biased GLP-1 receptor agonism — we say so.

Disclaimer

Not medical advice. Shop Tirzepatide is a product-design reference and is not affiliated with any manufacturer, vendor, pharmacy, or prescriber. The dose information summarizes the U.S. prescribing information and published trial protocols; it is not a personal recommendation. Tirzepatide is a prescription-only medication in the United States. Decisions about whether it is appropriate, and at what dose, belong with a licensed clinician who knows the patient's history.